Clinical Observation of the Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium in Patients With Non-small Cell Lung Cancer
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Sintilimab (Primary) ; Sugemalimab (Primary) ; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
Most Recent Events
- 03 Jan 2024 Status changed from active, no longer recruiting to completed.
- 21 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Jan 2024.
- 04 Dec 2023 Planned number of patients changed from 70 to 84.